Details for Patent: 4,760,071
✉ Email this page to a colleague
Summary for Patent: 4,760,071
Title: | 17.beta.-N-monosubstituted carbamoyl-4-aza-5.alpha.-androst-1-en-3-ones which are active as testosterone 5.alpha.-reductase inhibitors |
Abstract: | This invention is for the compound 17.beta.-(N-t-butylcarbamoyl)-4-aza-5.alpha.-androst-1-en-3-one, pharmaceutical compositions containing the compound, methods of inhibiting testosterone 5.alpha.-reductase with the compound and methods of treating hyperandrogenic conditions with the compound, particularly benign prostatic hypertrophy. |
Inventor(s): | Rasmusson; Gary H. (Watchung, NJ), Reynolds; Glenn F. (Westfield, NJ) |
Assignee: | Merck & Co., Inc. (Rahway, NJ) |
Application Number: | 06/800,623 |
Patent Claim Types: see list of patent claims | Use; Composition; | More… ↓ |
Drugs Protected by US Patent 4,760,071
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 4,760,071
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 0155096 | ⤷ Subscribe | SPC/GB93/006 | United Kingdom | ⤷ Subscribe |
European Patent Office | 0155096 | ⤷ Subscribe | 93C0055 | Belgium | ⤷ Subscribe |
Austria | 46912 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |